Download MendeleyDiscovery of sulfonamides and 9-oxo-2,8-diazaspiro[5,5]undecane-2-carboxamides as human kynurenine aminotransferase 2 (KAT2) inhibitors.
Kalliokoski, T., Rummakko, P., Rantanen, M., Blaesse, M., Augustin, M., Ummenthala, G.R., Choudhary, S., Venalainen, J.(2020) Bioorg Med Chem Lett 30: 127060-127060
- PubMed: 32113843
- DOI: https://doi.org/10.1016/j.bmcl.2020.127060
- Primary Citation of Related Structures:
6T8P, 6T8Q - PubMed Abstract:
Human kynurenine aminotransferase 2 (KAT2) inhibitors could be potentially used to treat the cognitive deficits associated with bipolar disease and schizophrenia. Although, there has been active drug research activity by several industrial and academic groups in developing KAT2 inhibitors over the years, no such compound has proceeded to the clinics. Here, we report two different chemical series of reversible KAT2 inhibitors with sub-micromolar activities. The first series was identified by a high-throughput screening of a diverse random library and the second one by structure-based virtual screening. Two novel crystal structures of KAT2 complexed with different reversible inhibitors were also deposited to the Protein databank which could be useful for future drug discovery efforts.
Organizational Affiliation:
Orion Pharma, Orionintie 1A, 02101 Espoo, Finland. Electronic address: tuomo.kalliokoski@orionpharma.com.
